CYP4V2 Gene Therapy Vector for Bietti's Crystalline Dystrophy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are ineffective for treating Bietti's crystalline dystrophy (BCD), a rare genetic disease causing retinal degeneration due to CYP4V2 gene mutations, which affect fatty acid metabolism and lead to lipid deposition and vision loss.
Innovation Solution
A vector comprising a polynucleotide encoding CYP4V2 with a specific promoter is used for gene therapy, effectively expressing the CYP4V2 protein in retinal cells, reducing lipid deposition, restoring fatty acid metabolism, and enhancing phagocytosis, thereby improving retinal function and vision.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene therapy using CYP4V2 is applied to treat BCD, then retinal function and visual function are improved, but the complexity of the treatment increases
Solution Approach 1:
A viral vector is used as an intermediary carrier to deliver the CYP4V2 gene into retinal cells. The vector includes specific promoter sequences (RPE65 promoter, CAG promoter) that enable targeted expression in retinal pigment epithelium cells, achieving therapeutic effect while managing delivery complexity through a well-characterized molecular vehicle
Solution Approach 2:
The patent optimizes multiple parameters including promoter selection (RPE65 vs CAG), vector type (AAV serotypes), and gene sequence variants to achieve optimal expression levels. Clinical trials tested different dosages (1×10^10 to 1×10^12 vg/eye) and administration methods to determine the optimal treatment parameters
2Reliability
If CYP4V2 gene expression is enhanced in retinal cells, then lipid deposition is reduced and fatty acid metabolism is restored, but the difficulty of detecting and measuring treatment efficacy increases
Solution Approach 1:
The patent uses lipid staining techniques that produce visible color changes to detect lipid deposition in retinal cells. BODIPY or Oil Red O staining shows lipid accumulation as red or fluorescent signals, providing a visual and quantifiable measure of treatment efficacy on fatty acid metabolism
Solution Approach 2:
The patent employs multiple assessment methods including electroretinogram (ERG) to measure retinal electrical activity, lipid staining to quantify lipid deposition, and molecular biology techniques to assess CYP4V2 expression levels. These feedback mechanisms provide comprehensive evaluation of treatment efficacy on both metabolic and functional levels
Data Source
AI summary
The present application relates to a vector comprising a polynucleotide encoding CYP4V2 and a promoter operably linked to the polynucleotide encoding CYP4V2. The vector described herein has a good expression effect, high expression speed, and more stable expression intensity. The present application also provides cells, pharmaceutical compositions, and kits comprising the vector, and methods for treating, alleviating, and/or preventing a disease or disorder associated with retinal pigment epithelium (RPE) atrophy.